Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,300 | 601 | 36.1% |
| Consulting Fee | $11,043 | 5 | 32.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,750 | 6 | 19.8% |
| Honoraria | $3,390 | 1 | 9.9% |
| Travel and Lodging | $431.00 | 10 | 1.3% |
| Education | $171.98 | 3 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $8,327 | 97 | $0 (2022) |
| Amgen Inc. | $7,631 | 141 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $4,391 | 46 | $0 (2024) |
| UCB, Inc. | $3,702 | 22 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $3,697 | 6 | $0 (2023) |
| Janssen Biotech, Inc. | $1,346 | 26 | $0 (2023) |
| Genentech USA, Inc. | $954.40 | 65 | $0 (2019) |
| GENZYME CORPORATION | $704.26 | 29 | $0 (2020) |
| Lilly USA, LLC | $597.80 | 40 | $0 (2021) |
| PFIZER INC. | $578.39 | 56 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $882.87 | 10 | UCB, Inc. ($403.80) |
| 2023 | $6,613 | 21 | Novartis Pharmaceuticals Corporation ($3,450) |
| 2022 | $9,632 | 52 | Amgen Inc. ($5,103) |
| 2021 | $329.89 | 10 | UCB, Inc. ($191.83) |
| 2020 | $539.28 | 30 | Lilly USA, LLC ($142.87) |
| 2019 | $3,604 | 208 | Amgen Inc. ($667.07) |
| 2018 | $5,542 | 135 | AbbVie, Inc. ($2,524) |
| 2017 | $6,942 | 160 | AbbVie, Inc. ($4,944) |
All Payment Transactions
626 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $58.90 | General |
| Category: Immunology | ||||||
| 08/27/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $75.64 | General |
| 06/26/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $54.80 | General |
| 05/14/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $97.84 | General |
| Category: Dermatology | ||||||
| 04/12/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $181.96 | General |
| 04/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $79.97 | General |
| Category: Immunology | ||||||
| 02/26/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $115.76 | General |
| 02/01/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $68.83 | General |
| 01/18/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $123.57 | General |
| 01/12/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $25.60 | General |
| 12/19/2023 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,070.00 | General |
| 12/19/2023 | UCB, Inc. | — | Travel and Lodging | Cash or cash equivalent | $24.89 | General |
| 11/03/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $105.29 | General |
| 07/11/2023 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $77.44 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 07/10/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $58.14 | General |
| Category: Immunology | ||||||
| 06/09/2023 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $49.04 | General |
| 06/08/2023 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $119.32 | General |
| Category: Inflammation | ||||||
| 03/03/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | COSENTYX (Drug) | Consulting Fee | Cash or cash equivalent | $3,325.00 | General |
| Category: Dermatology | ||||||
| 03/02/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $119.52 | General |
| Category: Dermatology | ||||||
| 02/28/2023 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $128.24 | General |
| 02/22/2023 | Amgen Inc. | Prolia (Biological) | Food and Beverage | In-kind items and services | $94.29 | General |
| Category: Bone Health | ||||||
| 02/13/2023 | Amgen Inc. | Enbrel (Biological), TAVNEOS | Food and Beverage | In-kind items and services | $9.84 | General |
| Category: Inflammation | ||||||
| 02/07/2023 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $134.59 | General |
| 02/06/2023 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Education | In-kind items and services | $79.99 | General |
| Category: Cardiology | ||||||
| 02/02/2023 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $104.48 | General |
| Category: Inflammation and Autoimmunity | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 498 | 8,386 | $512,524 | $134,934 |
| 2022 | 7 | 423 | 1,240 | $245,301 | $57,995 |
| 2021 | 5 | 396 | 576 | $218,613 | $50,612 |
| 2020 | 8 | 460 | 607 | $158,160 | $38,217 |
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 43 | 2,700 | $172,800 | $49,078 | 28.4% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 14 | 5,040 | $141,120 | $39,507 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 245 | 428 | $156,648 | $35,575 | 22.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 39 | 39 | $18,564 | $5,003 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 44 | 49 | $12,642 | $2,640 | 20.9% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 36 | 36 | $3,888 | $1,319 | 33.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 18 | 22 | $3,982 | $1,028 | 25.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 59 | 72 | $2,880 | $783.36 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 216 | 375 | $142,281 | $32,879 | 23.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 11 | 660 | $42,240 | $11,416 | 27.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 68 | 68 | $33,671 | $7,361 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 50 | 55 | $14,751 | $3,213 | 21.8% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 42 | 42 | $4,582 | $1,442 | 31.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 14 | 18 | $6,852 | $1,441 | 21.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 22 | 22 | $924.00 | $242.90 | 26.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 209 | 363 | $137,547 | $31,797 | 23.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 80 | 80 | $39,050 | $9,410 | 24.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 58 | 78 | $29,577 | $6,431 | 21.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 35 | 41 | $10,885 | $2,455 | 22.6% |
| 77080 | Bone density measurement of the core or central skeleton (e.g., hips, pelvis, spine) | Office | 2021 | 14 | 14 | $1,554 | $519.54 | 33.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 140 | 232 | $74,704 | $17,013 | 22.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 73 | 99 | $30,668 | $8,427 | 27.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 67 | 67 | $32,629 | $7,552 | 23.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 28 | 34 | $7,548 | $1,774 | 23.5% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 22 | 22 | $6,996 | $1,658 | 23.7% |
About Dr. Paramvir Sidhu, MD
Dr. Paramvir Sidhu, MD is a Internal Medicine healthcare provider based in Goodyear, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1124220116.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paramvir Sidhu, MD has received a total of $34,086 in payments from pharmaceutical and medical device companies, with $882.87 received in 2024. These payments were reported across 626 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($12,300).
As a Medicare-enrolled provider, Sidhu has provided services to 1,777 Medicare beneficiaries, totaling 10,809 services with total Medicare billing of $281,759. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location Goodyear, AZ
- Active Since 06/03/2007
- Last Updated 04/14/2017
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1124220116
Products in Payments
- EVENITY (Biological) $5,164
- LUPKYNIS (Drug) $3,697
- COSENTYX (Drug) $3,548
- Enbrel (Biological) $1,206
- STELARA (Biological) $1,108
- KEVZARA (Drug) $757.71
- COSENTYX (Biological) $749.85
- Rituxan (Biological) $696.07
- Humira (Biological) $646.65
- XELJANZ (Drug) $521.28
- Prolia (Biological) $492.45
- ORENCIA (Biological) $352.77
- ACTHAR (Biological) $301.12
- TALTZ (Drug) $293.06
- Actemra (Biological) $240.96
- OPSUMIT (Drug) $228.13
- FORTEO (Drug) $190.02
- BENLYSTA (Biological) $175.72
- RINVOQ (Biological) $171.31
- RAYOS (Drug) $168.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Goodyear
Deepanshu Garg, M.d, M.D
Internal Medicine — Payments: $16,357
Dr. Sharad Chandrika, M.d, M.D
Internal Medicine — Payments: $14,448
Dr. Manav Jasrotia, Md, MD
Internal Medicine — Payments: $13,861
Dr. Dat Tran, M.d, M.D
Internal Medicine — Payments: $3,570
Jared Berkowitz, M.d, M.D
Internal Medicine — Payments: $2,953
Supriya Bhardwaj, Md, MD
Internal Medicine — Payments: $2,822